Search
Displaying all 6 results
Adagrasib
go.drugbank.com/drugs/DB15568
ApprovedInvestigational
Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosph...
Locally advanced KRAS G12C Positive Colorectal Cancer
go.drugbank.com/conditions/DBCOND0168811Drugs: AdagrasibMetastatic KRAS G12C Positive Colorectal Cancer
go.drugbank.com/conditions/DBCOND0168812Drugs: AdagrasibBatoprotafib
go.drugbank.com/drugs/DB19137InvestigationalBatoprotafib is under investigation in clinical trial NCT04330664 (Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)).
Locally Advanced Non-Small Cell Lung Cancer
go.drugbank.com/conditions/DBCOND0039376Metastatic Non-Small Cell Lung Cancer
go.drugbank.com/conditions/DBCOND0043377